TBPHTheravance Biopharma, Inc.

$716M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+24.4% YoY

Gross Profit

$4M31.4% margin

Operating Income

-$16M-117.3% margin

Net Income

-$16M-113.8% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+32.0%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$13M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$447M

Total Liabilities

$166M

Stockholders' Equity

$280M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$11M	+24.4%
Gross Profit	$4M	-$4M	+211.6%
Operating Income	-$16M	-$23M	+30.2%
Net Income	-$16M	-$8M	-91.0%

Revenue Segments

YUPELRI Monotherapy

$19M58%

Viatris collaboration agreement

$14M42%

Collaboration revenue

$6,0000%

TBPH Q2 2023 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena